Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > The Four Dollar Barrier Wall

<< Previous

Bullboard Posts

Next >>

Comment by Inthepezon Feb 02, 2021 5:06pm

145 Views

Post# 32452900

RE:RE:RE:RE:The Four Dollar Barrier Wall

Actuarial wrote: Don't forget. When you participated in the PP, you paid $4 and you recieved 1 common share and 1/2 warrants. If you could sell your common share for $4, you basically received 1/2 warrants for free. If the share price moving down, you have no risk; if ATE acquired by a big pharm for a price higher than $6 (very likely it will for M&A scenario), you make hugh profit. If you do this, downside risk is zero, upside opportunity is unlimited. Why you say make no sense?

Actually it was 1 share plus 1/3 warrant

<< Previous

Bullboard Posts

Next >>

Consumer advocacy law firm investigates Microsoft over X-Box data concerns